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Objective: The objective of the study was to systematically review the literature for studies reporting gene expression
analyses (GEA) of the biological processes involved in early human peri-implant bone healing.
Methods: Electronic databases (MEDLINE, EMBASE) were searched in duplicate. Controlled and uncontrolled studies
reporting GEA of human peri-implant tissues - including ≥5 patients and ≥2 time points - during the first 4 weeks of
healing were eligible for inclusion. Methodological quality and risk of bias were also assessed.
Results: Four exploratory studies were included in reporting GEA of either tissues attached to SLA or SLActive implants
after 4 to 14 days or cells attached to TiOBlast or Osseospeed implants after 3 to 7 days. A total of 111 implants from 43
patients were analyzed using validated array methods; however, considerable heterogeneity and risk of bias were
detected. A consistent overall pattern of gene expression was observed; genes representing an immuno-inflammatory
response were overexpressed at days 3 to 4, followed by genes representing osteogenic processes at day 7. Genes
representing bone remodeling, angiogenesis, and neurogenesis were expressed concomitantly with osteogenesis.
Several regulators of these processes, such as cytokines, growth factors, transcription factors, and signaling pathways,
were identified. Implant surface properties seemed to influence the healing processes at various stages via differential
gene expression.
Conclusion: Limited evidence from gene expression studies in humans indicates that osteogenic processes
commence within the first post-operative week and they appear influenced at various stages by implant
surface properties.
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Introduction
Osseointegrated oral implants are an integral part of
modern reconstructive dentistry and are associated with
favorable long-term therapeutic outcomes [1]. Osseoin-
tegration was originally defined as the direct contact be-
tween vital bone and a load-bearing implant observed at
the light microscopic, i.e., histological, level [2]. Morpho-
genesis of implant osseointegration has been assessed in
several preclinical in vivo and clinical histological studies
[3-6], providing the basis for understanding the bio-
logical process.
The biological events during the early phase of
osseointegration are directly influenced by the osseous* Correspondence: andreas.stavropoulos@mah.se
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in any medium, provided the original work is pmicroenvironment (i.e., cells, signaling molecules, and
matrix) into which the implant is placed and have many
similarities with general wound healing mechanisms [7].
Implant surgery induces trauma, resulting in bleeding
and fibrin clot formation and an inflammatory reaction
that dominate the events of the first post-operative week.
The deposition of vital new bone on the implant surface
by osteoblasts (osteogenesis), a fundamental requirement
for osseointegration, occurs via secretion of a complex
extracellular matrix (ECM) of proteins, which subsequently
undergoes mineralization to form bone [8,9]. Primary
(woven) bone lined by osteoblasts can indeed be observed
on the implant surface already after 1 week [3,5]. In
parallel, removal of the created bone debris and remod-
eling of necrotized bone (due to the pressure exerted
by the implant) is underway. Replacement of woven
bone by organized and mechanically superior lamellaris an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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(depending on the species) and progressively increases
until woven bone is almost entirely replaced (8 to 12 weeks).
These events, including the nutrition of the newly formed
tissue, are sustained through concomitantly occurring
angiogenesis, i.e., formation of new blood vessels from
existing ones [10,11]. Thus, osseointegration is a dynamic
process whereby bone formation and remodeling occur in
parallel around the implant [4,6].
Morphogenesis of osseointegration and assessment of
the degree of bone-to-implant contact is usually performed
by means of histological evaluation [12], while the under-
lying molecular processes may be more precisely evaluated
at genetic level [13,14]. Data from gene expression analyses
of fracture healing provide the basis for understanding
these processes [15]. These studies have identified the cells,
signals, and interactions governing the key processes of
bone regeneration. Bone-forming osteoblasts are primarily
derived from marrow-resident multipotent progenitor cells
(mesenchymal stem cells (MSCs)), which are recruited to
the regeneration site. This process of MSC recruitment
and differentiation along the osteogenic lineage is termed
as osteoinduction and is controlled primarily by various
pro/anti-inflammatory cytokines (CKs) and by growth
factors (GFs) secreted by inflammatory cells and/or os-
teoblasts or by GF resident within the extracellular matrix
(e.g., bone morphogenetic proteins (BMPs)) in response to
injury [16-18]. Moreover, CKs and GFs act as signaling
molecules via specific signaling pathways and guide the
process of cell differentiation in the proper temporal se-
quence [19,20]. Intermediaries in this process are various
bone-specific transcription factors (TFs), which act as
‘molecular switches’ during cell differentiation and are
targets of CKs and GFs [21]. TFs facilitate bone-specific
gene transcription and ultimately gene expression by
which MSCs undergo differentiation and acquire the
osteoblastic phenotype [22]. While GFs regulate mainly
osteoinduction and osteogenesis, pro-inflammatory CKs
regulate the antagonist process of bone resorption by
inducing the differentiation of hematopoietic stem cells
(HSCs) into osteoclasts and macrophages [23], contrib-
uting to the dynamic nature of bone regeneration and
remodeling.
Recent in vitro [24] and preclinical in vivo [25] studies
have focused on the early molecular biological responses
to various titanium implant surfaces. Understanding these
early responses is essential for efforts aiming to accelerate
and enhance the process of osseointegration [26]. Upregu-
lation or downregulation of specific genes in peri-implant
tissues identified by analyses of genetic material (DNA,
RNA) reflects the nature and timing of the various healing
processes, which in turn could be potential ‘molecular
targets’ for enhancing osseointegration [27,28]. The aim
of the present study was to systematically review theavailable literature on gene expression analyses of the




A study protocol for a systematic qualitative literature
review was developed based on recommended methods
[29]. The focused question was ‘what biological processes
are reflected by gene expression analyses in peri-implant
tissues of humans during the early stages (up to 4 weeks)
of healing?’
Inclusion and exclusion criteria
All studies, controlled (using different implants) or un-
controlled, reporting gene expression analyses of peri-
implant tissues harvested from ≥5 human patients at ≥2
time points during the first 4 weeks of healing, were
eligible for inclusion. Studies reporting the use of either
‘experimental’ (micro) or standard implants with clear
description of implant surface properties, placed in the
maxilla or mandible and retrieved at a later time point,
were eligible for inclusion. Studies reporting (1) analyses
of peri-implant mucosa or sulcular fluid or peri-implant
tissues of failing or infected implants (peri-implantitis), (2)
only histological or immunohistochemical analyses with-
out gene expression of harvested tissues, and (3) in vitro
and preclinical in vivo studies were excluded. Primary out-
come of interest was the biological process (or processes)
reflected by gene expression at a particular time point of
peri-implant tissue healing.
Search strategy
Electronic databases of MEDLINE (via PubMed) and
EMBASE were searched by one author (SS) for rele-
vant English-language literature up to and including
June 2014. The search strategy used for MEDLINE was
((((("gene expression" OR transcriptome OR transcriptional
OR molecular OR microarray))) AND ((osseointegration
OR healing OR "peri implant"))) AND implants) AND
((human OR humans OR patients OR subjects)). Unpub-
lished literature was searched via the Google and Google
Scholar search engines. Additionally, the bibliographies of
all relevant studies and review articles were searched.
Study selection
Titles and abstracts of the search identified studies were
screened by two authors (SS and VS) based on the inclu-
sion criteria, and full texts of all eligible studies were
obtained. Differences in assessment of eligibility were
resolved by discussion with the third author (AS). Full
texts were independently reviewed by both reviewers,
and final inclusion was based on the aforementioned
inclusion criteria.
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Both reviewers independently extracted data from the
full texts of included articles using specially designed forms.
Data on author(s), study design, implant type/surface,
any additional procedures performed, number of patients
(in each group), presence of a control group, procedure
and time of implant retrieval, methods of gene expression
analysis, and main results, were extracted. Descriptive
summaries of the studies were entered into tables, and
a qualitative synthesis of evidence was planned. Any
disagreement between the reviewers regarding data ex-
traction was resolved by discussion.
Assessment of methodology and risk of bias
Assessment of the methodological validity of the included
studies was performed using criteria adapted from previ-
ous reports [30,31]. Aspects of study design, genotyping
methods, and data analyses were considered using nine
criteria (Table 1).
The risk of bias in the included studies was assessed
using an adaptation of published guidelines for reporting
systematic reviews of periodontal genetic association stud-
ies [32]. Mainly, aspects of study design and methodo-
logical validity were assessed using 15 criteria and scored
as ‘yes,’ ‘no,’ or ‘unclear’ based on the information provided
in the study manuscript (Table 2). Moreover, publishedTable 1 Assessment of the genotyping methodology in the in
Methodology Ivanovski et al. [34] Donos et al. [35]
Tissue harvesting Tissue attached to implant
carefully removed with a
curette, preexisting hard
tissue discarded
Tissue attached to implan
carefully removed with a
curette and homogenized















Studio v3 software, raw
probe expression values
extracted
Bead Station 500/ Bead
Studio v3 software, raw
probe expression values
extracted
Processing Noisy data discarded Noisy data discarded
Clustering GO categories (DAVID
tool)
GO categories (DAVID too
Statistical analysis Gene Spring software Gene Spring software
Comparisons Pair-wise comparisons
between three time
points (4 vs. 7 days, 7
vs. 14 days, and 4 vs.
14 days)
Pair-wise comparisons at
each time point (4, 7, and
14 days) between SLA and
SLActive surfaces
GO, gene ontology; DAVID, Database for Annotation, Visualization and Integrated Dguidance [33] regarding the qualitative and quantitative
syntheses of results from genetic association studies was
consulted, and heterogeneity across the included studies
was assessed to explore the possibility of a meta-analysis.
Results and discussion
The included studies basically report on commercially
available implants from two major manufacturers and in-
volve comparisons of different implant surface technologies
in regard with topography and/or chemistry modifications
within each implant system. Various analyses were per-
formed in the included studies; however, an attempt has
been made to synthesize the various findings and discuss
them herein irrespective of the specific implant systems,
based on the assumption that basic biological mechanisms
of peri-implant bone wound healing are largely implant
system independent.
Search results and study characteristics
Of the 242 search identified studies, only four studies
were finally included in the review, all focusing on the
impact of implant surface on early human peri-implant
bone healing (Figure 1; Table 3). Genetic analyses of total
RNA isolated from either newly formed peri-implant bone
harvested by trephination [34,35] or from cells adherent
to implants retrieved by reverse threading [36,37] werecluded studies
Bryington et al. [36] Thalji et al. [37]
t Implants removed by reverse
threading and homogenized;
cell lysates isolated





Total RNA isolation, purification,
quantity/quality analysis and
biotin-labeling
RT-PCR (custom RT-PCR array




Human Gene 1.1 ST)
RT2 SYBR Green qPCR Master
Mix/7500 Real-Time PCR system




l) Osteogenesis genes; cytokine-
related genes
GO categories (Gene Spring)
RT2 Profiler software Gene Spring software
T-test to evaluate differences
between each implant surface
per time point
Two-way ANOVAs to determine
differences between implant
surface type and time points;
pair-wise comparisons of each
implant surface independently
at different time points (day 7
vs. day 3)
iscovery.
Table 2 Assessment of risk of bias and heterogeneity within and across the included studies
Category Ivanovski et al. [34] Donos et al. 2011 [35] Bryington et al. [36] Thalji et al. [37]
Study design
Comparison None (only SLActive) SLA vs. SLActive TiOBlast vs. Osseospeed TiOBlast vs. Osseospeed
Setting University University University University
Population, inclusion
criteria
9 healthy volunteers with
no mandibular third molars,
no contraindications for oral
surgery; age 21 to 48,
median 29 years
9 healthy volunteers with
no mandibular third
molars; age 21 to 48,
median 29 years
6 women, 4 men; implant
patients, systemically healthy
(no HTN, diabetes, CVD); age
25 to 58, mean 36.2 years
9 women, 2 men; implant
patients, systemically healthy;
age 47 to 69, mean 60.2 years











Comparability of groups Unclear Unclear Unclear Unclear
Potential confounders,
e.g., post-op medication
Unclear Unclear Unclear Unclear
Power calculation No No No No
Statistical correction For multiple sampling For multiple sampling Unclear For multiple sampling
Methods
Tissue analyzed Peri-implant tissue Peri-implant tissue Implant-adherent cells Implant-adherent cells
Genetic material
analyzed
Total RNA Total RNA Total RNA Total RNA
Success rate Unclear 16/18 samples (88.8%) 7/10 subject samples (70%) Unclear
Genotyping method Microarray Microarray RT-PCR Whole-genome microarray
Genotype counts Yes Yes Yes Yes
Blinding Unclear Unclear Yes Unclear
Reproducibility, validated
genotyping accuracy
No No No No
All studies were judged to be at a high risk of bias with substantial heterogeneity across studies.
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analyzed. All four studies reported the use of commercially
existing implant surfaces, i.e., either a chemically modified,
hydrophilic, sand-blasted, acid-etched surface (SLActive®,
Institute Straumann AG, Basel, Switzerland); or aFigure 1 Flowchart for study selection (n = number of studies).hydrophilic (SLActive®) versus a hydrophobic unmodi-
fied SLA® (Institute Straumann AG, Basel, Switzerland)
surface; or a micro-topographic titanium-oxide grit-
blasted surface (TiOBlast®, AstraTech, Molndal, Sweden)
versus a chemically modified nano-topographic grit-blasted
Table 3 Summary of findings from the included studies (n = 4)
Study Ivanovski et al. [34] Donos et al. [35] Bryington et al. [36] Thalji et al. [37]
Design 9 patients; 9 implants placed 18 patients; 18 implants
placed
10 patients; 60 implants
placed
11 patients; 44 implants placed
Total RNA extracted from
peri-implant tissue
(trephine)
16 samples analyzed 42 samples analyzed Total RNA extracted from implant
adherent cells (reverse thread)
Total RNA extracted from
peri-implant tissue (trephine)
Total RNA extracted from
implant adherent cells
(reverse thread)
Surface SLActive SLA vs. SLActive TiOBlast vs. Osseospeed TiOBlast vs. Osseospeed
GE day 3/4 Upregulated Upregulated on SLA Upregulated on both surfaces No significant differences between
surfaces at any time point (P > 0.05)
CKs (TNF-a, IL-6, IL-2) Neurogenesis Osteogenesis (Runx2, Osx,
BMP6, OPN)
Results presented as GE at day 7 vs.
day 3 for each surface
Immune-inflammatory cells
(LC, MP)
Collagen organization Inflammatory CKs (IL-1A,B,
TNF)
Inflammatory NF-kB p/w Upregulated on SLActive MP activity
Ras protein p/w Upregulated on Osseospeed
Collagen organization Chemotaxis (CCL18, CXCL10,
CXCL14)
CK response Anti-inflammatory CKs
(TOLLIP, IL9, IL22)
GE day 7 Upregulated Upregulated on both surfaces Upregulated on both surfaces Upregulated on both surfaces
MSC genes (HOX, Sp3) Inflammatory CKs (IL1, IL2,
IL6, TNFS)
Osteogenesis (Runx2, Osx*,
OCN*, OPN, BMP6, BSP)
ECM (Coll, GPs, PGs)
GF (TGF-B receptor) Neurogenesis [* Osseo > TiOB; P < 0.05] Collagen organization (PLODs, LOX,
PCOLCE)
VEGF sig. (vs. day 14) Upregulated on SLActive Angiogenesis/VEGF sig. (ANXA,
EPAS1)
Wnt p/w Neurogenesis (BDNF,
NTF3)
Ossification
Downregulated ECM (OPN) Remodeling (MMPs, TIMPs)
Inflammatory NF-kB p/w
(vs. day 4)
BMP p/w (BMP4, BMP2K) Osteoclastic (CTSK, ACP5)
MAPK sig. Chemotaxis (CKs, MP activity)
Mineralization Anti-inflammatory CKs (CCL22,
CCL18)
Focal adhesion (integrins) Downregulated on both surfaces
Angiogenesis (VEGF sig.,
P13-Akt p/w)
Inflammatory CKs (IL1A, IL1B)
Downregulated on SLActive
Inflammatory cells (LC)
GE day 14 Upregulated Upregulated on both
surfaces
-
ECM (Coll, OC, ON, ALP) BMP p/w (BMP4, BMP2K)
TFs (Osx, Dlx5, Twist1, Smad6) Downregulated on both
surfaces
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GE, gene expression; CKs, cytokines; p/w, pathway; MSC, mesenchymal stem cells; GF, growth factors; sig., signaling; ECM, extracellular matrix; TFs, transcription
factors; MP, macrophage; LC, lymphocytes; GPs, glycoproteins; PGs, proteoglycans.
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Implant retrieval times were at 3 or 4 days and
7 days in all studies and additionally at 14 days in
two studies [34,35].
Assessment of methodology and risk of bias
All studies used validated methods for gene expression
analysis; genetic data was analyzed using microarray (three
studies) or real-time PCR (RT-PCR) (one study) methods
(Table 1). Total RNA was isolated from lysates of either
trephined peri-implant tissues or implant-adherent cells,
and subjected to microarray processing or RT-PCR.
Although moderate-to-good agreement has been re-
ported between the two methods, validation of DNA
microarray results by the more sensitive PCR array is
generally recommended [38]. None of the microarray
studies identified have validated their results using
RT-PCR. Genotyping data (gene lists) were imported
and analyzed using computer software and further
condensed into functionally and biologically relevant
categories. Nevertheless, differential gene expression
in relation to a particular cell type or region of tissue
analyzed was not performed [35]. Gene ‘upregulation’
was reported when genes were expressed at a higher
level on one implant surface in comparison to another; in
context, differentiation between gene expression and over-
expression may be difficult to define. Statistical methods
were used to compare differences in gene expression
between different time points and/or implant surfaces
(P < 0.05 significance level), while correcting for possible
errors, i.e., false gene discovery rate due to multiple sam-
pling [39]. There was considerable heterogeneity across
the included studies in terms of study design, population,
implant surface technology, genotyping methods, and data
analyses (Table 2). Therefore, no meta-analysis of associ-
ation between gene expression and implant surface prop-
erties was relevant.
Thus, high risk of bias should be considered when
interpreting the results, due to the above methodological
limitations and the overall limited information (four
studies) available.Biological processes identified through gene expression
in peri-implant tissues
Conventional implant surgery involves osteotomy prep-
aration and insertion of the implant into the alveolar bone.
The immediate local effects of this procedure, functionally
relevant to subsequent healing processes, are (1) bone
trauma, (2) formation of bone debris, (3) hemostasis and
clot formation, and (4) hypoxia. These effects involve
the release of specific CKs and GFs within the local en-
vironment [7], resulting in recruitment of two primary
cell types to the site, inflammatory cells and progenitor
cells (MSCs and HSCs) [19], which in turn regulate the
subsequent healing processes. A summary of differen-
tially regulated genes relating to the involved biological
processes is presented in Table 4, while Figure 2 repre-
sents an evidence-based illustrative model summarizing
these processes.
Inflammation
All studies reported a significant upregulation of genes
associated with inflammation during the first time point
of observation (day 3 or 4) regardless of the implant sur-
face. Specifically, upregulation regarded pro-inflammatory
cytokines of the interleukin (IL), tumor necrosis factor
(TNF), and interferon (IFN) families, as well as genes asso-
ciated with proliferation of lymphocytes and macrophages
(MPs). Previous in vitro [40,41] and animal [42] studies
have reported the significance of MPs at the bone-implant
interface and identified favorable MP activity in relation to
modified rough surfaces as demonstrated by in vitro gene
expression that was associated with increased in vivo bone
formation. Also, the nuclear factor-kB (NF-kB) inflamma-
tory pathway was upregulated at day 4 [34], while macro-
phage activity and chemokines of the CCL and CXL
families in the peri-implant tissues continued to remain
prominent at day 7.
However, this inflammatory response was generally down-
regulated at later time points (day 7 or 14). For example, in
one study, genes associated with pro-inflammatory cytokines
(IL-1B, IL-1A, IL-1R2) and chemokines (CCL22, CCL18)
were downregulated and upregulated, respectively, on day 7,
Table 4 Summary of biological processes and associated






Tumor necrosis factor (TNF-a, TNFSF9)
Interleukin (IL-6, IL-2, IL-1 F9, IL-23A, IL-6ST)
Interferon (IFNA2)




Toll interacting protein (TOLLIP)
Cells Lymphocyte, macrophage negative proliferation
(BTLA, LST1)
Macrophage scavenger receptor (MSR1)






Transforming GF (TGF-b, TGF-b receptor 1, 2
and 3, TGF-a)
Platelet-derived GF (PDGF receptor)
Bone morphogenetic proteins (BMP4, BMP6,
BMP receptor 1A, BMP2-K)
Growth and differentiation factor (GDF10)
Wnt frizzled receptor (FZD3, FZD8, FRZB)
Notch (NOTCH2)
Ras-protein signal transduction (RAP1B, RAP1A,
RASGRP4)




‘Master switches’ [RUNX2, SP7 (OSX)]
Homeobox (DLX1, DLX5, HOXD12, MSX1,
HOXA5, HOXB1, HOXB6, HOXC6)




Collagen (Col1A1, Col12A1, Col6A3, Col3A1,
Col6A1, Col11A1, Col11A2, Col13A1, Col5A2)
Non-collagen proteins [BGLAP (OC), SPARC (ON),
SPP1 (OP), BSP, IBSP, POSTN, ECM1]
Small leucine-rich proteoglycans (SLRP) (DCN,
BGN, LUM)










Table 4 Summary of biological processes and associated
genes reported in the included studies (Continued)
Osteoclast activity/
remodeling
Cathepsin K (CTSK, CTSK-receptor)
Tartarate-resistant acid phosphatase (TRAP/ACP5)
Matrix metallopeptidase (MMP2, MMP12, MMP9,
MMP7, MMP13)
Tissue inhibitor metallopeptidase (TIMP2, TIMP3)
Angiogenesis Vascular endothelial GF-signaling (EPAS1, ANXA2,
EGR1-binding protein)
Phosphatidyl-inositol 3-kinase (PI3K)-Akt signaling
Neurogenesis Brain-derived neurotrophic factor (BDNF)
Neurotrophin 3 (NTF3)
NK2 homeobox 2(NKX2-2)
Tubby-like protein 3 (TULP3)
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and TiOBlast) [37]. Moreover, the anti-inflammatory re-
sponse seemed to be modulated by surface properties. In
one study, genes related to anti-inflammatory cytokines such
as IL-9, IL-22, toll-like receptor inhibitor protein (TOLLIP),
and several key chemokines (CCL18, CXCL10, CXCL18)
were significantly upregulated on Osseospeed surfaces but
not TiOBlast, at day 3 [36]. In another study, genes associ-
ated with inflammatory cell proliferation were significantly
downregulated earlier on SLActive surfaces compared to the
SLA, i.e., at day 7 instead of day 14 [35]. Therefore, the
initial inflammatory response seems to be important for
the recruitment of cells that govern subsequent healing
processes and is regulated by a natural biological immune
response which may be further modified by implant
surface properties.
Osteogenic differentiation
Cells along the osteogenic differentiation pathway may
be artificially categorized as (1) undifferentiated MSCs,
(2) osteo-chondro-progenitor cells, (3) pre-osteoblasts,
and (4) osteoblasts; although in reality, a developmental
continuum without distinct boundaries may exist [43].
While pre-differentiated osteoblasts in the marrow com-
partment only play a minor role in bone wound healing,
a more prominent role is that of undifferentiated MSCs
which are recruited to the regeneration site where they
differentiate into osteoblasts [16]. The recruitment and
differentiation of MSCs is regulated by CKs and GFs
[17,19]. The GFs most commonly implicated in bone
wound healing are BMPs, members of the TGF-β family,
PDGF, and IGF-1 [19,20]. Moreover, the bone debris cre-
ated during implant surgery, the peri-implant blood clot
(i.e., platelets) and the differentiating MSCs themselves
further contribute to release of GFs at the site [44,45].
All studies reported some evidence of osteogenic dif-
ferentiation at an early time point (day 3 or 4) via
Figure 2 Summary of biological processes identified via gene expression during early peri-implant bone healing. CKs, cytokines;
GFs, growth factors; EPC, endothelial progenitor cells; EC, endothelial cells; MSC, mesenchymal stem cells; OB, osteoblasts; ECM, extracellular
matrix; HSC, haematopoietic stem cells; MP, macrophages; OC, osteoclasts.
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(bone morphogenetic proteins (BMP4, BMP6, BMP2-
kinase), growth and differentiation factor-10 (GDF10),
transforming growth factors (TGF-α, TGF-β), platelet-
derived growth factor (PDGF), and insulin-like growth
factor-1 (IGF1)), transcription factors (Runx2, Osx, Dlx3,
Dlx5, Msx1, HOX genes, Sp1, Sp3), and/or osteogenic
signaling pathways (TGF-β/BMP signaling, Wnt-receptors,
Ras-protein/mitogen-activated protein kinase (Ras/MAPK)
signal transduction). In all studies, these genes were further
upregulated at day 7. Upregulation of osteogenic factors
seemed regulated by implant surface. The key transcription
factor osterix (Osx) was upregulated on the Osseospeed
surface, but not TiOBlast at day 7 [36], while tissues adja-
cent to SLActive surfaces demonstrated comparatively
greater BMP and Ras/MAPK expression compared to SLA
surfaces at day 7 [35]. Previous in vivo animal studies have
reported correlations between upregulated osteogenic gene
expression in peri-implant tissues and enhanced histo-
logical and biomechanical measures of osseointegration
during early (1- to 4-week) healing times [27,46]; neverthe-
less, it is unclear whether upregulation and/or overexpres-
sion of genes at a specific time point directly correlates to
increased protein production in vivo.The key signaling pathways, via which GFs guide
osteogenic cell differentiation, are the TGF-β/BMP- and
Wnt-mediated pathways [19,47]. While the BMP pathway
ensures differentiation of MSCs into osteo-chondro-
progenitors (OCPs), the Wnt pathway is essential for
subsequent osteoblastic commitment, i.e., Wnt acts
‘downstream’ of BMP to ensure that OCPs differentiate
into osteoblasts and not chondroblasts [47]. Genes as-
sociated with both TGF-β/BMP and Wnt pathway (Wnt
receptors) were upregulated at day 7 [34,35] and day 14
[34] on SLA and SLActive surfaces, suggesting the oc-
currence of osteogenic differentiation at these time points.
GF-regulated signaling pathways exert their effects on
differentiating cells via activation of TFs. The TFs Runx2
and Osx are considered as ‘master switches’ and absolute
requirements for osteoblast differentiation [21] - while
Runx2 is essential for MSC differentiation, Osx acting
‘downstream’ of Runx2 controls osteoblastic fate deter-
mination [48,49]. An upregulation of these genes was
observed in relation to the TiOBlast, Osseospeed, and
SLActive surfaces in the present review. However, at
day 7, expression of Osx was significantly greater on
Osseospeed than TiOBlast surfaces. This finding is con-
sistent with previous animal [50,51] and human studies
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amount of bone-to-implant contact occurring earlier)
of Osseospeed versus TiOBlast implants was reported.
Thus, it appears that implant surface topography and/
or chemistry influence peri-implant bone healing in
humans both at the signaling pathway and transcrip-
tion factor level.ECM production
Deposition of new bone on the implant surface involves
the secretion of a complex ECM (scaffold) of proteins by
osteoblasts, which subsequently undergoes mineralization
[9]. Expression of ECM proteins is a reliable indicator of
early osteogenic activity [19] and was identified in all four
studies at days 7 and 14. All studies reported some
evidence of ECM production and/or organization at
days 7 and 14. Upregulated genes associated with ECM
deposition included various collagens (Col 1 to 11),
non-collagen proteins (osteopontin (OPN), osteonec-
tin (ON), osteocalcin (OCN), bone sialoprotein (IBSP),
periostin (POSTN), and ECM protein-1), alkaline phosphat-
ase (ALP), and bone-specific adhesion proteins (integrins
(ITGB4, ITGB5), laminins (LAMA2, LAMA3), and cadher-
ins (CDH11)). Osteocalcin, the most bone-specific ECM
protein and a late marker of osteogenic differentiation [19],
was significantly upregulated on Osseospeed (versus
TiOBlast) surfaces at day 7 [36]. Osteopontin, an ECM
protein essential for mineralization [53], was significantly
upregulated on SLActive comparing to SLA surfaces at
day 7 [35]. The possibility that implant surface features
enhance osteogenic differentiation of MSCs via upregula-
tion of specific genes (e.g., SLActive versus SLA in regard
with BMP and Wnt signaling) has been demonstrated
in vitro [54].
Furthermore, genes associated with collagen fibril for-
mation/organization (heat-shock protein-47 (HSP-47),
pro-collagen C-endopeptidase enhancer (PCOLCE), small
leucine-rich proteoglycans (SLRP)) and post-translational
modification (pro-collagen lysyl-hydroxylases (PLOD1,
PLOD2, PLOD3) and lysyl-oxidase (LOX)) were upregu-
lated on Osseospeed and TiOBlast surfaces [37]. Collagen
comprises approximately 90% of the ECM and collagen
fibrillogenesis and organization directly determine the
biomechanical properties of bone [55,56]. Genes associ-
ated with collagen fibril formation, maturation, and post-
translational modification expressed by osteoblasts [57,58]
were upregulated on TiOBlast and Osseospeed implants,
representing early ECM organization at the bone-implant
interface. These modifications determine the pattern of
collagen cross-linking which in turn influences tissue
organization, mineralization, and ultimately mechanical
bone strength [56], and in the case of osseointegration,
the integrity of the bone-implant interface [37].Osteoclastic activity and remodeling
While GFs regulate osteogenesis, pro-inflammatory CKs
(e.g., IL-1, IL-6, TNF-α) simultaneously regulate the an-
tagonist process of bone resorption via osteoclasts [23].
Moreover, osteoblasts themselves stimulate osteoclasto-
genesis via macrophage colony stimulating factor (M-CSF)
and receptor activator of NF-kB ligand (RANKL) genes
but also closely regulate this process via osteoprotegerin
(OPG), an inhibitor of RANKL [59].
Two studies reported expression of genes associated with
osteoclastic activity and ECM degradation (cathepsin-K
(CTSK), tartarate-resistant acid phosphatase (ACP5), and/
or matrix metalloproteinases (MMPs)), on Osseospeed
and TiOBlast surfaces at day 7 [37], and SLActive sur-
faces at day 14. However, upregulation of MMP inhibi-
tors (TIMP-2, -3) was also reported on TiOBlast and
Osseospeed surfaces suggesting a control of the resorp-
tion process. Although no studies reported differential
RANKL/OPG expression, a previous in vitro study [60]
reported significant downregulation of osteoclastogenic
genes on SLActive surfaces. Collectively, these data re-
affirm the dynamic nature of bone formation and resorp-
tion at the implant-bone interface, even in early healing
stages, and suggest the possibility for implant surface tech-
nology modulation of bone remodeling.
Angiogenesis
Angiogenesis is closely related to osteogenesis and occurs
simultaneously during bone regeneration [11]. Physiological
oxygen tensions in bone are about 12.5% O2 but fall to 1%
O2 in regeneration sites due to disruption of the local
vasculature as a result of injury and/or surgery [61,62]. A
key event that stimulates angiogenesis (and osteogenesis)
at regeneration sites is hypoxia, via the hypoxia inducible
(transcription) factor-1 (HIF-1) that regulates expression
of angiogenic genes [63]. The key cells involved in angio-
genesis are macrophages, which in response to hypoxia
and inflammation release chemotactic and angiogenic
growth factors (e.g., VEGF) [40,64], and endothelial pro-
genitor cells (EPCs) which differentiate into endothelial
cell lining blood vessels [65]. VEGF is the single most
important regulator of EPC differentiation and vessel
formation [66]. Moreover, a role for VEGF in osteogenic
differentiation has also been suggested mainly via inter-
action with the BMP signaling pathway [67].
In the present review, a significant simultaneous upregu-
lation of several angiogenesis-related genes was identified
at day 7 in all included studies. Pro-angiogenic factors
(ANXA2, EPAS-1) were upregulated at TiOBlast and
Osseospeed surfaces at day 7 [37]. Genes associated
with VEGF and P13K-AKT signaling pathways were up-
regulated at SLActive (but not SLA) surfaces on day 7
and continued to be upregulated on day 14 [35]. The
P13K-AKT pathway is reported to be important for
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in addition to aiding VEGF-mediated angiogenesis [68].
Previous in vitro studies have reported the pro-angiogenic
effects of SLActive surfaces by promoting VEGF expres-
sion in EPCs and osteoblasts [65,69], while enhanced
histological osseointegration of SLActive implants has
been directly correlated with increased angiogenesis in
a dog model [70,71]. Thus, implant surface technology
appears to have the possibility to also influence angio-
genesis at early stages of wound healing.
Neurogenesis
Bone innervation includes both myelinated and unmyelin-
ated nerve fibers located in the periosteum, bone cortex,
Haversian systems, Volkmann’s canals, and the marrow
spaces [72]. An interesting finding in the present review
was the significant upregulation of genes associated with
neurogenesis, more than any other biological process, on
SLActive and SLA surfaces at all time points [34,35]. Spe-
cific processes represented were axon formation, growth
and differentiation, and the neural signaling pathway. This
is consistent with previous in vivo reports of murine frac-
ture healing [73] and calvarial defect regeneration in rela-
tion to SLA surfaces [74,75]. Key neurotrophic factors
(brain-derived neurotrophic factor (BDNF) and neurotro-
phin 3 (NTF3)), essential for neuronal survival and dif-
ferentiation during development [76], were significantly
upregulated on SLActive versus SLA surfaces at day 7
suggesting an effect of surface modulation. The P13K-
AKT pathway, upregulated on SLActive surfaces (in
relation to angiogenesis), has also been implicated in
neuronal survival and subsequent neural development
[77,78] and could have contributed to upregulation of
neurogenic genes at these surfaces. Indeed, previous
histologic reports have described changes in bone in-
nervation after implant placement (and loading) and the
presence of nerve fibers within the peri-implant bone, in
animals and humans [79-81].
It can be hypothesized that peri-implant neurogenesis
is one of the underlying mechanisms governing the
phenomenon of osseoperception, defined as the tactile
sensibility of osseointegrated implants to occlusal forces
induced via activation of nerve endings and/or receptors
in the peri-implant environment [82,83]. Moreover, re-
cent evidence suggests that implant surface properties
may influence the degree of osseoperception in humans
[84], which can be correlated with the genomic evidence
for implant surface modulation of neurogenesis during
osseointegration.
Finally, the present review findings are consistent with
a recent gene expression study of healing extraction sockets
in humans [85]. This study reported an initial upregulation
of pro-inflammatory cytokines (IL-1, IL-6) at day 1, but
by day 7, genes suggestive of immune response (IL-10),osteogenesis (TGF, BMP4, BMP7, OCN and ALP), and
angiogenesis (VEGF) were upregulated, continuing until
day 14, suggesting that the basic biological processes
governing alveolar wound healing and osseointegration
are the same.Conclusions
Based on limited evidence of gene expression data from
four studies involving 43 patients, the following remarks
can be made:
1. Early peri-implant healing (2 weeks) involves a
sequence of biological events which are similar to
those observed in other bone wound healing
scenarios (fractures, extraction-sockets).
2. Osseointegration depends on osteogenesis at the
implant interface, but other simultaneously
occurring processes such as inflammation, bone
resorption, angiogenesis and neurogenesis also play
an important role, as evidenced by consistent and
concomitant gene expression.
3. Several genes associated with key regulators of
biological processes, such as cells, cytokines, growth
factors, transcription factors, signaling pathways,
and secretory products, were shown to be
differentially regulated during peri-implant healing
in a manner that was largely consistent - in terms of
nature and timing - with previous in vitro and
preclinical in vivo histological studies of
osseointegration.
4. Implant surface technology can influence
osseointegration, at every step of the early wound
healing process, i.e., anti-inflammatory response,
progenitor cell recruitment, osteoinduction, growth
factor/transcription factor expression, signaling
pathway regulation, and extracellular matrix
production. However, the relevance of those
observations is questionable; no distinct differences
have been demonstrated in terms of histological
outcomes at later time points or short- and long-term
clinical performance among the various implant
surface technologies discussed herein.
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